Contrast-Enhanced Ultrasound in the Diagnosis of Gallbladder Diseases: A Multi-Center Experience

Lin-Na Liu¹, Hui-Xiong Xu^{1,2*}, Ming-De Lu^{2*}, Xiao-Yan Xie², Wen-Ping Wang³, Bing Hu⁴, Kun Yan⁵, Hong Ding³, Shao-Shan Tang⁶, Lin-Xue Qian⁷, Bao-Ming Luo⁸, Yan-Ling Wen⁹

1 Department of Medical Ultrasound, Tenth People's Hospital of Tongji University, Shanghai, China, 2 Department of Medical Ultrasonics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, 3 Department of Ultrasound, Zhongshan Hospital of Fudan University, Shanghai, China, 4 Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated 6th People's Hospital, Shanghai, China, 5 Department of Ultrasound, Peking University School of Oncology, Beijing Cancer Institute, Beijing, China, 6 Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, China, 7 Department of Ultrasound, Beijing Friendship Hospital, Capital Medical University, Beijing, China, 8 Department of Ultrasound, Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 9 Department of Ultrasound, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Abstract

Objective: To assess the usefulness of contrast–enhanced ultrasound (CEUS) in differentiating malignant from benign gallbladder (GB) diseases.

Methods: This study had institutional review board approval. 192 patients with GB diseases from 9 university hospitals were studied. After intravenous bonus injection of a phospholipid-stabilized shell microbubble contrast agent, lesions were scanned with low acoustic power CEUS. A multiple logistic regression analysis was performed to identify diagnostic clues from 17 independent variables that enabled differentiation between malignant and benign GB diseases. Receiver operating characteristic (ROC) curve analysis was performed.

Results: Among the 17 independent variables, multiple logistic regression analysis showed that the following 4 independent variables were associated with the benign nature of the GB diseases, including the patient age, intralesional blood vessel depicted on CEUS, contrast washout time, and wall intactness depicted on CEUS (all P<0.05). ROC analysis showed that the patient age, intralesional vessels on CEUS, and the intactness of the GB wall depicted on CEUS yielded an area under the ROC curve (Az) greater than 0.8 in each and Az for the combination of the 4 significant independent variables was 0.915 [95% confidence interval (CI): 0.857–0.974]. The corresponding Az, sensitivity, and specificity for the age were 0.805 (95% CI: 0.746–0.863), 92.2%%, and 59.6%; for the intralesional vessels on CEUS were 0.813 (95% CI: 0.751–0.875), 59.8%, and 98.0%; and for the GB wall intactness were 0.857 (95% CI: 0.786–0.928), 78.4%, and 92.9%. The cut-off values for benign GB diseases were patient age <53.5 yrs, dotted intralesional vessels on CEUS and intact GB wall on CEUS.

Conclusion: CEUS is valuable in differentiating malignant from benign GB diseases. Branched or linear intralesional vessels and destruction of GB wall on CEUS are the CEUS features highly suggestive of GB malignancy and the patient age >53.5 yrs is also a clue for GB malignancy.

Citation: Liu L-N, Xu H-X, Lu M-D, Xie X-Y, Wang W-P, et al. (2012) Contrast-Enhanced Ultrasound in the Diagnosis of Gallbladder Diseases: A Multi-Center Experience. PLoS ONE 7(10): e48371. doi:10.1371/journal.pone.0048371

Editor: Masaru Katoh, National Cancer Center, Japan

Received April 23, 2012; Accepted September 24, 2012; Published October 31, 2012

Copyright: © 2012 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by Grant 2008-2-10 of Public Welfare Research Special Project from Chinese Ministry of Health and Grant 20114003 from Key Project of Shanghai Health Bureau. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: xuhuixiong@hotmail.com (H-XX); lumd@live.com (M-DL)

Introduction

Ultrasound (US) examination is accepted as the primary imaging modality in the assessment of gallbladder (GB) disease, which is ascribed to its inherent superiority in comparison to other imaging modalities such as real-time scanning, easy manipulation, cost-effectiveness, no radiation, high resolution, and repeatability. In addition, GB is particularly suitable for US scanning since the echo contrast between GB lesions and the bile in the GB is obvious in most cases, which makes it easy for the delineation of the GB diseases [1,2,3,4]. GB cancer is an uncommon malignancy but highly lethal with a median survival of 6 months, indicating that the majority of patients present with advanced disease. Despite the widespread use of modern imaging techniques, early diagnosis is rare because there are no specific signs and symptoms, and many GB carcinomas are not diagnosed preoperatively. Despite of its obvious superiority, US has difficulty to make definite diagnosis for GB carcinoma under some circumstances [4,5,6]. The differential diagnosis includes the more frequently encountered inflammatory conditions of the gallbladder, adenomyomatosis, polyps, biliary sludge, and other hepatobiliary malignancies. Therefore, it is necessary to develop new US techniques to

improve the diagnosis of GB diseases and facilitate the early diagnosis of GB carcinoma.

Contrast-enhanced ultrasound (CEUS) under low acoustic power allows clear depiction of macro- and micro- circulation of target organ, which in turn improves the detection and characterization of lesions in various organs such as liver, kidney, pancreas, and so on [7,8,9,10]. Although CEUS has been tentatively used in GB diseases, the role of CEUS in GB is less well recognized and multicenter experience is not available [10,11,12,13,14,15,16]. In this prospective study, the application of GB CEUS in 9 centers was reported with an aim to evaluate the role of CEUS in the differential diagnosis between benign and malignant GB diseases.

Materials and Methods

Ethics Statement

This prospective study received approvals from the institutional ethical committees of the 9 university hospitals as follows.

1. Ethical committee of Tenth People's Hospital of Tongji University.

- 2. Ethical committee of The First Affiliated Hospital of Sun Yat-Sen University.
- 3. Ethical committee of Zhongshan Hospital of Fudan University.
- 4. Ethical committee of Shanghai Jiao Tong University Affiliated 6th People's Hospital.
- 5. Ethical committee of Peking University School of Oncology, Beijing Cancer Institute.
- 6. Ethical committee of Shengjing Hospital of China Medical University.
- 7. Ethical committee of Beijing Friendship Hospital of Capital Medical University.
- 8. Ethical committee of Second Affiliated Hospital of Sun Yat-sen University.
- 9. Ethical committee of Sixth Affiliated Hospital of Sun Yat-sen University.

All patients gave written informed consent after the procedure has been carefully explained to the patient. The clinical investigation has been conducted according to the principles expressed in the Declaration of Helsinki.



Figure 1. Morphological type and intralesional blood vessels in the gallbladder lesion. Upper left, polypoid type; upper middle, thickened-wall type; upper right, mass-forming type. Lower left, scattered blood vessels; lower middle, linear blood vessels; lower right, branched blood vessels. doi:10.1371/journal.pone.0048371.g001



Figure 2. Enhancement extent of the gallbladder lesions on contrast-enhanced ultrasound. Upper left, non-enhancing; upper right, hyper-enhancing; lower left, iso-enhancing; lower-right, hypo-enhancing (arrows indicate the lesions). doi:10.1371/journal.pone.0048371.g002

Study Population

The patients were recruited for CEUS when they met the following criteria: (1) GB diseases found at primary US examinations: (2) Referral for exclusion of malignancy by clinicians or radiologists; (3) Patient age 18 to 80 years old; (4) Absence of severe cardiopulmonary diseases; (5) Not pregnant or lactating; (6) Diagnoses confirmed by pathological examination or surgery. Patients that showed typical US findings of gallbladder stones, debris, and small polypoid lesions (equal to or less than 0.5 cm in diameter) were excluded from the study. Finally, between 2007 and 2010, 192 patients were included in this study. Eight-three (43.2%) of them were male and 109(56.8%) were female. The age range of the patients was 21 to 80 years old and the mean age (standard deviation, std) was 52 (15) years old. In 161(83.9%) patients, only single lesion was found, whereas in the remaining 31 (16.1%) patients, multiple lesions were detected. In the patients with multiple lesions, generally the largest lesion on US was selected for analysis; however, if the largest lesion was inconspicuous on US, the most conspicuous one of the remaining lesions was selected for analysis.

Ultrasound Technique

The following US systems were used: Acuson Sequoia 512 (Contrast pulse sequencing, CPS) (Siemens Medical Solutions, Mountain View, CA), Aplio XV (Contrast harmonic imaging, CHI) (Toshiba Medical System, Tokyo, Japan), IU 22 (Pulse inversion imaging) (Philips Medical Systems, Bothell, Wash); LOGIQ 9 (Coded phase inversion, CPI) (GE Healthcare, Milwaukee, WI); and Esaote DU8 (Contrast tuned imaging, CnTI) (Italy). Since different US systems were used in this multi-center study, the study protocol was standardized prior to implementation. All the transducers were required to be abdominal use and the frequency of the transducers ranged from 1.0 to 6.0 MHz. Contrast specific imaging (CSI) modes were available for all the systems and the range of the mechanical index (MI) for the CSI modes was 0.05 to 0.20, which enables effective tissue cancellation to generate almost pure microbubble images and avoids destruction of microbubbles in the circulation. The machine settings were optimized with the help of the engineers from the manufacturers after review of the study protocol. Uniform imaging setting was used for the same type of system.

Baseline US and CEUS were performed by radiologists with more than five years' experience in liver US and at least two years' experience with CEUS in liver. The US examination was performed according to the following standardized protocol, assessed at a consensus meeting prior to the study. Before the start of the study, several tentative cases with GB diseases received CEUS using different US systems in each center according to the standardized protocol. The baseline US and CEUS images were



Figure 3. Intactness of the gallbladder wall on contrast-enhanced ultrasound. Left, the gallbladder wall (arrow) beneath an adenoma is intact. Right, the gallbladder wall (arrow) beneath a cancer (arrowheads) is destructed and the infiltration to the adjacent liver (arrow) is observed. doi:10.1371/journal.pone.0048371.g003

send to the coordinators for check to ensure that the CEUS procedures were standardized and the quality of the data met the requirement. After the start of the study, a medium-term inspection was carried out that the coordinators visited all the centers and reviewed the relevant data to guarantee the standardization of the procedures.

All the patients underwent fasting at least 8 h before US examination. Each patient underwent a complete examination of the GB and the adjacent liver under baseline US before CEUS. The thickness of the GB wall and the maximal diameter of the GB lesions were measured on US. A second-generation blood pool agent, BR1 (SonoVue), consisting of phospholipid-stabilized shell microbubbles filled with sulfur hexafluoride gas, was used in this study. In each case, a dose of 1.5 to 2.4 mL SonoVue was administered via the antecubital vein in a bolus fashion (within 1–2 s), followed by a flush of 5 mL of 0.9% normal saline by using a 20-gauge cannula. The doses for the different systems were recommended by the manufacturers, and generally same dose was used for the same machine.

CEUS was performed after baseline US. The target lesion was placed in the center of the screen and the transducer was kept in a stable position. The imaging mode was changed to CEUS, and the MI settings were adjusted to provide sufficient tissue cancellation with the maintenance of adequate depth penetration. Focus was positioned just below the bottom of the lesion and maintained the same position during the examination. A stopwatch was started at the time of SonoVue administration. CEUS images were recorded continuously for a period of 120 s immediately after the injection, without any change in the machine settings. After 120 s, the transducer was moved to scan the adjacent liver tissue. The vascular phases of the GB are different from those of the liver because the blood supply is provided entirely by the cystic artery and not by portal vein branches. The arterial phase is followed by the venous phase [10]. The timing of the CEUS phases were as follows: arterial phase (<30 s) and venous phase (31–120 s) [10]. After 120 s, the transducer was moved to scan the liver to exclude the liver infiltration or liver metastasis. Baseline US images and CEUS cine clips were stored digitally on the hard disks in the imaging systems, and were transferred to a personal computer for subsequent analysis.

Image Analysis

Baseline US images and CEUS cine clips were evaluated by two experienced investigators with consensus. Both investigators had more than 4 years' experience in GB CEUS. Before the image analysis, several tentative cases were allocated to the 2 investigators for evaluation and discussion unless a high interobserver agreement was achieved. The baseline US and CEUS images were randomized for presentation so that the GB diseases were not grouped by diagnosis, and any identifying information (i.e. the site number, the case sequence number, name, sex and age of each patient) was concealed. The investigators were anonymous to the final diagnoses of the GB diseases and were blind to the clinical relevant data such as laboratory tests and other imaging results.

Characteristic Inductor (inclusion) Inductor (incl								
Adventorial problemation of the problematio	ristics Malignan	t (n=51) Benign (n=141)						ă,
Date Anticipant Anticipant </th <th></th> <th>Cholesterol polyp (n=63)</th> <th>Adenoma (n=21)</th> <th>Adenomyomatosis (n = 14)</th> <th>Chronic cholecystitis (n = 31)</th> <th>Biliary sludge (n = 12)</th> <th>Total (n = 141)</th> <th></th>		Cholesterol polyp (n=63)	Adenoma (n=21)	Adenomyomatosis (n = 14)	Chronic cholecystitis (n = 31)	Biliary sludge (n = 12)	Total (n = 141)	
Gendler (MalteFremale) 223 1344 813 95 1714 57 Age (yr) manucul (310) (412) (413) (413) (413) (413) (413) Age (yr) manucul (310) (412) (413) (41								
Qa (ya) mendidi G3(0) G3(1) G3(1) G4(1) G4(2) G4	(Male/Female) 25/26	19/44	8/13	9/5	17/14	5/7	58/83	0.410
more (min - max) (28-78) (24-74) (21-86) (26-74) (26-74) (26-74) Single lesion/Milple lesions 48.3 41/23 17.3 1.0 2.3 9.3 Single lesion/Milple lesions 48.3 41/23 10.3 1.0 3.10 9.3 Sie (m) mean (std) 45(2.9) 1.10.5) 2.3(0.9) 1.2(0.5) 1.4 3.12.0) 9.3 Sie (m) mean (std) 3 (5.9%) 1.10.5) 2.44% 0.6-3.3) 1.45% 9.3 Si (0 mean (std) 0.6-147) 1.66% 3.45% 0 1.45% 1.64% 3.72.0) 9.3 Si (0 mean (std) 0.6 1.16% 3.166.7) 1.16% 3.166.7) 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.66.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3% 1.64.3%	:) mean(std) 63(10)	45(12)	49(18)	46(10)	54(14)	48(17)	48(14)	< 0.001
Single lesion/unlique lesions 43 41/23 13/2 13/1 10/0 93 Lesion 1 <td< td=""><td>nin - max) (28–78)</td><td>(24–74)</td><td>(21–86)</td><td>(26–61)</td><td>(25–74)</td><td>(26–76)</td><td>(21–86)</td><td></td></td<>	nin - max) (28–78)	(24–74)	(21–86)	(26–61)	(25–74)	(26–76)	(21–86)	
Introduct of the second	ssion/Multiple lesions 48/3	41/22	19/2	13/1	31/0	9/3	113/28	0.020
See (cm) mean (std) 45(2.9) 1.1(0.5) 2.3(0.9) 1.2(0.5) 1.6(1.4) 3.7(1.1) ange (min - max) (65-14.7) (05-3.3) (12-4.4) (06-2.3) (10-4.50) (10-8.0) 2.1 (11-2.0) (35.9%) (35.9%) (35.9%) (36.7%) (35.9%) (10-8.0) (13.9%) (10-8.0) 2.1 (11-2.0) (35.9%) (35.9%) (11.6%) (31.4.3%) (17.9%) (31.6.9%) (16.9%)								
Independent (0.6-1.4) (0.5-3.4) (1.2-4.4) (0.6-2.3) (0.4-5.8) (0.6-3) 51 cm 3 (57.1%) 0 (7.0%) 3 (57.1%) 0 (7.0%) 15(4.4%) (10.80) 51 cm 3 (57.1%) 1 (1.6%) 3 (57.1%) 3 (57.1%) 15(3.6%) 15(3.6%) 15(3.9%) 15(3	1) mean (std) 4.5(2.9)	1.1(0.5)	2.3(0.9)	1.2(0.5)	1.6(1.4)	3.7(2.1)	1.7(1.3)	< 0.001
1000000000000000000000000000000000000	nin - max) (0.6–14.7)	(0.5–3.3)	(1.2–4.4)	(0.6–2.3)	(0.4–5.8)	(1.0–8.0)	(0.4–14.7)	
11-20 cm 8 (15.%) 25 (39.%) 13 (61.9%) 6 (42.9%) 8 (25.%) 21 (6.%)	3 (5.9%)	36 (57.1%)	0	7(50.0%)	15(48.4%)	1 (8.3%)	59(41.8%)	< 0.001
21-30 cm $6 (118\%)$ $1 (16\%)$ $3 (13\%)$ $3 (7.\%)$ <	8 (15.7%)	25 (39.7%)	13(61.9%)	6(42.9%)	8(25.8%)	2(16.7%)	54(38.3%)	
> 30 cm $3 (6.5)$ $1 (1.6%)$ $5 (2.3%)$ 0 $5 (16.1%)$ $7 (8.3%)$ location $3 (6.5)$ $1 (1.5%)$ $1 (1.5%)$ $2 (9.5%)$ 0 $5 (16.1%)$ $7 (8.3%)$ location $1 (0.15%)$ $1 (0.15%)$ $1 (0.15%)$ $1 (6.7%)$ $7 (5.0%)$ $7 (6.1%)$ $7 (1.5%)$ location $1 (0.19%)$ $1 (1.175%)$ $1 (6.7%)$ $1 (6.7%)$ $2 (1.2%)$ $2 (1.7%)$ $2 (1.7%)$ location $1 (0.19%)$ $1 (1.175%)$ $1 (1.75%)$ $1 (1.75%)$ $2 (1.2%)$ $2 (1.7%)$ $2 (1.7%)$ location $2 (2.3%)$ 0 $2 (1.2%)$ $2 (1.7%)$ $2 (1.7%)$ $2 (1.7%)$ location $1 (1.175%)$ $2 (1.17%)$ $1 (1.7%)$ $2 (1.7%)$ $2 (1.7%)$ location $1 (1.16%)$ 0 0 $2 (1.2%)$ $2 (1.7%)$ location $2 (1.7%)$ 0 $2 (1.7%)$ $2 (1.7%)$ $2 (1.7%)$ location $1 (1.2%)$ $1 (1.2%)$ $1 (1.2%)$	6 (11.8%)	1 (1.6%)	3(14.3%)	1(7.1%)	3(9.7%)	2(16.7%)	10(7.1%)	
Interfacional control Incretion 2(3,5%) 0 1(3,2%) 0 Nek 0(15,6%) 10(19,6%) 10(15,6%) 10(19,6%) 10(19,6%) 10(19,6%) 10(19,6%) 10(19,6%) 10(19,6%) 11(17,5%) 2(3,6%) 7(3,0%) 7(3,2,6%) 5(1,6%) 5(1,7%) 5(34 (66.7)	1 (1.6%)	5(23.8%)	0	5(16.1%)	7(58.3%)	18(12.8%)	
Net 9 (17,6%) 10(15,9%) 10(11,9%) 10(11,9%) 10(1								
BodyBody $10(196\%)$ $11(75\%)$ $16(76.2\%)$ $7(50\%)$ $7(2.6\%)$ $5(41.\%)$ $5(41.\%)$ Bottom $10(196\%)$ $11(175\%)$ $3(14.3\%)$ $3(14.3\%)$ $5(16.\%)$ $5(16.\%)$ $5(1.5\%)$ </td <td>9 (17.6%)</td> <td>10(15.9%)</td> <td>2(9.5%)</td> <td>0</td> <td>1(3.2%)</td> <td>0</td> <td>13(9.2%)</td> <td>< 0.001</td>	9 (17.6%)	10(15.9%)	2(9.5%)	0	1(3.2%)	0	13(9.2%)	< 0.001
Bottom $10(196\%)$ $1(17,5\%)$ $3(14,3\%)$ $4(28.6\%)$ $5(16,1\%)$ $4(33.3\%)$ All $22(43,1\%)$ $1(1,6\%)$ 0 $3(1,4\%)$ $5(16,1\%)$ $4(33.3\%)$ Morphological Type $2(43,1\%)$ $1(1,6\%)$ 0 $3(12,9\%)$ $5(16,1\%)$ $6(50.0\%)$ Polypoid $18(35,3\%)$ 0 0 $7(50.0\%)$ $5(16,1\%)$ $6(50.0\%)$ 0 Polypoid $18(35,3\%)$ 0 0 $7(50.0\%)$ $5(16,1\%)$ $6(50.0\%)$ 0 Mass-forming $25(49.0\%)$ 0 $1(4.8\%)$ $1(7,1\%)$ $7(17\%)$ $5(16,1\%)$ $6(50.0\%)$ Mass-forming $25(49.0\%)$ 0 0 $1(4.8\%)$ $1(7,1\%)$ $2(16,7\%)$ $6(50.0\%)$ 0 Mass-forming $25(49.0\%)$ 0 $1(4.8\%)$ $1(7,1\%)$ $2(16,7\%)$ $2(16,7\%)$ $6(20.0\%)$ $2(16,7\%)$ $2(16,7\%)$ 0 Mass-forming $8(15,7\%)$ 0 $1(4.8\%)$ $1(17,1\%)$ $2(16,7\%)$ $2(16,7\%)$ $2(16,7\%)$ $2(16,7\%)$ $2(16,7\%)$ 0 Hyper $15(29,4\%)$ 0 $1(4.3\%)$ $7(33.3\%)$ $7(50.0\%)$ $2(14,7\%)$ $2(17.7\%)$ $2(17.7\%)$ Hyper $23(45,1\%)$ $2(14,3\%)$ $7(33.3\%)$ $7(26,0\%)$ $2(12,3\%)$ $2(12,3\%)$ $2(12,0\%)$ $2(12,0\%)$ Hyper $2(14,0\%)$ $2(14,0\%)$ $2(14,0\%)$ $2(14,0\%)$ $2(12,0\%)$ $2(12,0\%)$ $2(12,0\%)$ $2(20,0\%)$ Mixed $2(14,0\%)$ $2(14,0\%)$ $2(14,0\%)$ $2(14,0\%)$ $2(14,0\%)$ </td <td>10(19.6%)</td> <td>41(65.1%)</td> <td>16(76.2%)</td> <td>7 (50.0%)</td> <td>7(22.6%)</td> <td>5(41.7%)</td> <td>76(53.9%)</td> <td></td>	10(19.6%)	41(65.1%)	16(76.2%)	7 (50.0%)	7(22.6%)	5(41.7%)	76(53.9%)	
All $2(43.1\%)$ $1(1.6\%)$ 0 $3(21.4\%)$ $18(58.1\%)$ $3(25.0\%)$ Morphological Type $8(15.7\%)$ $63(100\%)$ $5(10\%)$ $5(16.1\%)$ $6(50.0\%)$ Polypoid $18(35.3\%)$ 0 0 $7(50.0\%)$ $5(16.1\%)$ $6(50.0\%)$ Morseforming $8(15.7\%)$ 0 0 $7(30,0)$ $21(67.7\%)$ $6(50.0\%)$ Masseforming $25(49.0\%)$ 0 0 $7(50.0\%)$ $5(16.1\%)$ $6(50.0\%)$ Masseforming $25(49.0\%)$ 0 $1(4.8\%)$ $1(7.1\%)$ $2(16.1\%)$ $6(50.0\%)$ Masseforming $2(13.3\%)$ 0 $1(7.1\%)$ $2(16.1\%)$ $6(50.0\%)$ More $25(49.0\%)$ 0 $1(7.1\%)$ $2(16.1\%)$ $5(16.1\%)$ $6(50.0\%)$ Hyper $15(2.9\%)$ 0 $1(7.1\%)$ $1(7.1\%)$ $2(16.1\%)$ $5(1.1\%)$ Hyper $15(3.3\%)$ $7(33.3\%)$ $7(30.0\%)$ $7(20.0\%)$ $2(13.7\%)$ Wited $2(9.5\%)$	10(19.6%)	11(17.5%)	3(14.3%)	4 (28.6%)	5(16.1%)	4(33.3%)	27(19.1%)	
Morphological Type (15.7%) 63(10%) 20(95.2%) 6(42.9%) 5(16.1%) 6 (50.0%) Polypoid 8 (15.7%) 63(100%) 20(95.2%) 6(42.9%) 5(16.1%) 6 (50.0%) Thickened wall 18(35.3%) 0 0 7(50.0%) 2(16.7%) 6 (50.0%) Mass-forming 25 (49.0%) 0 1(4.8%) 1(7.1%) 5(16.1%) 6 (50.0%) Mass-forming 25 (49.0%) 0 1(4.3%) 1(4.3%) 7 (50.0%) 5(16.1%) 6 (50.0%) Hyper- 8(15.7%) 8(15.7%) 0 1(4.3%) 7 (33.3%) 7 (50.0%) 5(16.1%) 6 (50.0%) Hyper- 15/294% 0 14(6.7%) 12(35.4%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(14.7%) 2(24.5%) 2(14.7%) 2(24.5%) 2(24.7%) 2(24.7%) 2(24.7%) <	22(43.1%)	1 (1.6%)	0	3 (21.4%)	18(58.1%)	3(25.0%)	25(17.7%)	
	gical Type							
Thickened wall $18(3.3.3\%)$ 0 (7.00%) $21(6.7\%)$ 0Mass-forming $25(49.0\%)$ 0 $1(4.8\%)$ $1(7.1\%)$ $5(16.1\%)$ $6(50.0\%)$ Mass-forming $25(49.0\%)$ 0 $1(4.8\%)$ $1(7.1\%)$ $5(16.1\%)$ $6(50.0\%)$ Kebogenicity $25(49.0\%)$ $18(5.7\%)$ $48(76.2\%)$ $14(6.7\%)$ $4(28.6\%)$ $8(25.8\%)$ $5(41.7\%)$ Hyper- $8(15.7\%)$ $2(14.3\%)$ $7(50.0\%)$ $7(20.0\%)$ $7(22.6\%)$ $4(33.3\%)$ Hypo- $23(45.1\%)$ 0 0 0 0 $1(3.2,7\%)$ $3(25.0\%)$ Hypo- $23(45.1\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ Hypo- $23(45.1\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ Hypo- $23(45.1\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ Mixed $5(9.8\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ Mixed $5(9.8\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ Mixed $5(9.8\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ Mixed $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ Mixed $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%)$ $0(9.5\%$	3 (15.7%)	63(100%)	20(95.2%)	6(42.9%)	5(16.1%)	6 (50.0%)	100(70.9%)	< 0.001
Mas-forming $25 (49.0\%)$ 0 $1(4.8\%)$ $1(7.1\%)$ $5(16.1\%)$ $6 (50.0\%)$ Ethogenicity $21 (4.9\%)$ $4(3.5\%)$ $4(3.6\%)$ $8(15.7\%)$ $8(15.7\%)$ $8(15.7\%)$ $8(15.7\%)$ $8(15.7\%)$ $8(15.7\%)$ $8(15.7\%)$ $8(13.7\%)$ $8(13.7\%)$ $8(13.7\%)$ $8(13.7\%)$ $8(13.7\%)$ $8(13.7\%)$ $8(13.3\%)$ $8(13.7\%)$ $8(13.3\%)$ $8(13.7\%)$ $8(13.3\%)$	ed wall 18(35.3%)	0	0	7(50.0%)	21(67.7%)	0	28(19.9%)	
EchogenicityEchogenicity $(15,7\%)$ $48(76.2\%)$ $14(66.7\%)$ (28.6%) $8(25.8\%)$ $5(41.7\%)$ Hyper- $8(15.7\%)$ $9(14.3\%)$ $7(33.3\%)$ $7(50.0\%)$ $7(22.6\%)$ $4(33.3\%)$ Iso- $15(29.4\%)$ $9(14.3\%)$ $7(33.3\%)$ $7(50.0\%)$ $7(22.6\%)$ $4(33.3\%)$ Hypo- $23(45.1\%)$ $6(9.5\%)$ 0 $3(21.4\%)$ $12(38.7\%)$ $3(25.0\%)$ Hypo- $23(45.1\%)$ 0 0 0 0 $4(12.9\%)$ 0 Mixed $5(9.8\%)$ 0 0 0 $1(21.4\%)$ 0 Vacularity $10(15.9\%)$ $10(15.9\%)$ $2(9.5\%)$ $6(42.9\%)$ $6(19.3\%)$ $11(91.7\%)$ None $5(9.8\%)$ $10(15.9\%)$ $12(57.1\%)$ $7(50.0\%)$ $18(58.1\%)$ $11(91.7\%)$ Scaree $27(52.9\%)$ 467.7% $2(9.5\%)$ $17(1\%)$ $17(1\%)$ $10(9.3\%)$ Hundart 1875.3% 167.3% $17(7.0\%)$ $17(1\%)$ $10(75.9\%)$ $10(9.9\%)$	ming 25 (49.0%)	0	1(4.8%)	1(7.1%)	5(16.1%)	6 (50.0%)	13(9.2%)	
Hyper- $8(15,7\%)$ $48(76,2\%)$ $14(66,7\%)$ $4(28,6\%)$ $8(25,8\%)$ $5(41,7\%)$ Iso- $15(29,4\%)$ $9(14,3\%)$ $7(33,3\%)$ $7(50,0\%)$ $7(22,6\%)$ $3(33,3\%)$ Hypo- $23(45,1\%)$ $6(9,5\%)$ $6(9,5\%)$ 0 0 $3(21,4\%)$ $12(38,7\%)$ $3(25,0\%)$ Hypo- $5(9,8\%)$ $6(9,5\%)$ 0 0 0 0 $3(21,4\%)$ $3(25,0\%)$ $3(25,0\%)$ Mixed $5(9,8\%)$ 0 0 0 0 0 0 0 Vacularity $10(15,9\%)$ $10(15,9\%)$ $2(9,5\%)$ $6(12,9\%)$ $6(19,3\%)$ $11(91,7\%)$ None $5(9,8\%)$ $10(15,9\%)$ $12(57,1\%)$ $7(50,0\%)$ $18(58,1\%)$ $11(91,7\%)$ Scarce $27(52,9\%)$ $4(7,3\%)$ $7(3,3\%)$ $17(1,0\%)$ $18(58,1\%)$ $18(3,9\%)$ Ahurdart $1875,3\%)$ $2(9,5\%)$ $2(9,5\%)$ $12(7,1\%)$ $10(1,9\%)$ $1(19,1\%)$	ity							
Iso- 15(29.4%) 9(14.3%) 7(33.3%) 7(50.0%) 7(22.6%) 4(33.3%) Hypo- 23(45.1%) 6(9.5%) 0 3(21.4%) 12(38.7%) 3(25.0%) Mixed 5(9.8%) 0 0 3(21.4%) 12(38.7%) 3(25.0%) Mixed 5(9.8%) 0 0 3(21.4%) 12(38.7%) 3(25.0%) Vacularity 5(9.8%) 0 0 0 4(12.9%) 0 Vacularity 1 10(15.9%) 2(9.5%) 6(42.9%) 6(19.3%) 11(91.7%) None 5 (9.8%) 10(15.9%) 2(9.5%) 5(42.9%) 6(19.3%) 11(91.7%) Scarce 27(52.9%) 4/77.8%) 12(57.1%) 7(50.0%) 18(58.1%) 1(83%) Ahundart 18(35.3%) 17(3.3%) 17(3.3%) 17(16%) 1(83%)	8(15.7%)	48(76.2%)	14(66.7%)	4(28.6%)	8(25.8%)	5(41.7%)	79(56.0%)	< 0.001
Hypo- 23(45.1%) 6(9.5%) 0 3(21.4%) 12(38.7%) 3(25.0%) Mixed 5(9.8%) 0 0 4(12.9%) 3(25.0%) Mixed 5(9.8%) 0 0 4(12.9%) 3(25.0%) Vascularity 1 1 1 1 1 Vascularity 5 (9.8%) 10(15.9%) 2(9.5%) 6(12.9%) 11(91.7%) None 2 (75.29%) 49(77.8%) 12(57.1%) 7(50.0%) 18(58.1%) 1(191.7%) Ahundart 18(35.1%) 18(53.3%) 1(71.0%) 7(75.0%) 1(8(3.9%)	15(29.4%)	9(14.3%)	7(33.3%)	7 (50.0%)	7(22.6%)	4(33.3%)	34(24.1%)	
Mixed 5(9.8%) 0 0 4(12.9%) 0 Vascularity Xascularity 5 (9.8%) 10(15.9%) 2(9.5%) 6(42.9%) 6(19.3%) 11(91.7%) None 2 (75.2.9%) 49(77.8%) 12(57.1%) 7(50.0%) 18(58.1%) 1(8.3%) Ahindart 18(75.3%) 4(6.3%) 7(3.3%) 1(7.1%) 7(72.6%) 0	23(45.1%)	6(9.5%)	0	3(21.4%)	12(38.7%)	3(25.0%)	24(17.0%)	
Vascularity Vascularity None 5 (9.8%) 10(15.9%) 2(9.5%) 6(42.9%) 6(19.3%) 11(91.7%) Scarce 27(52.9%) 49(77.8%) 12(57.1%) 7(50.0%) 18(58.1%) 1(8.3%) Abundant 18(35.3%) 4(6.3%) 7(33.3%) 1(71.0%) 7(73.6%) 0	5(9.8%)	0	0	0	4(12.9%)	0	4(2.8%)	
None 5 (98%) 10(15.9%) 2(9.5%) 6(42.9%) 6(19.3%) 11(91.7%) Scarce 27(52.9%) 49(77.8%) 12(57.1%) 7(50.0%) 18(58.1%) 1(8.3%) Abundant 18(34.3%) 4(6.3%) 2(33.3%) 1(71%) 7(75.6%) 0								0.001
Scarce 27(52.9%) 49(77.8%) 12(57.1%) 7(50.0%) 18(58.1%) 1(8.3%) Abundant 18(35.3%) 4/6.3%) 7(33.3%) 1(7.1%) 7(75.6%) 0	5 (9.8%)	10(15.9%)	2(9.5%)	6(42.9%)	6(19.3%)	11(91.7%)	35(24.8%)	
Abundant 18(35,3%) 4(6,3%) 7(33,3%) 1(7,1%) 7(2,5%) 0	27(52.9%)	49(77.8%)	12(57.1%)	7(50.0%)	18(58.1%)	1 (8.3%)	87(61.7%)	
	nt 18(35.3%)	4(6.3%)	7(33.3%)	1(7.1%)	7(22.6%)	0	19(13.5%)	

-

October 2012 | Volume 7 | Issue 10 | e48371

CEUS in the Diagnosis of Gallbladder Diseases

Andmemore features Mail prant (n=3) Advent features Advent features From Concent features 15,613,01 Advent features Advent features In=31,01 Advent features 15,613,01 13,613,01 Advent features In=31,01 Advent features 15,513,41 15,613,81 13,613,61 16,913,01 In=31,01 Advent feature 10,-232 15,314,01 18,913,81 13,613,61 16,913,01 16,913,01 Advent feature (sec) 10,-132 13,419,41 18,913,81 16,133,71 16,130,01 16,143,01 Advent feature (sec) 11,51,00 16,12,320 13,413,41 17,71 16,133,71 16,143,01 Advent feature (sec) 11,149,01 16,12,800 16,12,800 16,133,41 16,133,41 16,143,61 Advent feature (sec) 11,149,01 16,12,800 16,12,800 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61 16,143,61						
Cholesterol polys Adenomatoxis Chroni Francement time (n=33) Adenoma (n=21) (n=14) (n=14) Erhancement time (s=23) (s=33) (s=13) (s=14) (n=13) Arival time (sec) (s=23) (s=23) (s=23) (s=23) (s=23) (s=23) Arival time (sec) (s=12) (s=12) (s=12) (s=23) (s=24) (s=24) Arival time (sec) (s=14) (s=12) (s=12) (s=12) (s=14) (s=24) (s=14) Arange (nin - max) (s=12) (s=12) (s=12) (s=12) (s=14) (s=24) Arange (nin - max) (s=12) (s=12) (s=13) (s=14) (s=14) (s=14) Arange (nin - max) (s=11) (s=12) (s=13) (s=13) (s=14) (s=14) Arange (nin - max) (s=11) (s=12) (s=13) (s=13) (s=13) (s=14) Arange (nin - max) (s=13) (s=13) (s=13) (s=13) (s=14) (s=14)	Malignant (n = 51) Benign (n = 141)					Å,
Enhancement time range (min - maxi) 15/513.41 15/613.81 13/613.61 16/9(J) range (min - maxi) (9.2.2) (9.2.2) (9.2.2) (10.2.2) (10.2.1) range (min - maxi) (9.2.2) (11.2.7) (13.2.7) (13.2.7) (14.3.0) range (min - maxi) (10.2.1) (11.2.7) (11.2.7) (13.2.7) (14.3.0) range (min - maxi) (13.1.0) (13.1.0) (13.1.0) (13.1.0) (13.1.0) (13.1.0) (13.1.0) (13.1.0) (14.1.0) (14.3.0) </th <th>Cholesterol polyp (n = 63) Adenor</th> <th>Adenomyomato na (n = 21) (n = 14)</th> <th>sis Chronic cholecystitis (n=31)</th> <th>Biliary sludge (n = 12)</th> <th>Total[#] (n = 141)</th> <th></th>	Cholesterol polyp (n = 63) Adenor	Adenomyomato na (n = 21) (n = 14)	sis Chronic cholecystitis (n=31)	Biliary sludge (n = 12)	Total [#] (n = 141)	
Arrival time (sec) 155(3.4) 156(3.8) 13.6(3.8) 13.6(3.6) 16.9(4.3) range (min - max) (9.24) (9.24) (9.27) (7.22) (10.27) Time to peak (sec) 23.3(4.4) 18.9(3.8) 18.0(3.7) 20.804 Washou time (sec) 1(1-32) (11-27) (11-27) (11-27) (11-27) Washou time (sec) 14.4(19.4) 47.7(2.4.2) 87.3(3.4.7) 53.1(25) 62.4(3) Range (min - max) (15-120) (18-120) (18-120) (11-27) (14-30) Range (min - max) (15-120) (18-120) (17-170) (25-170) (25-13) Range (min - max) (19-36) 0 (11-27) (26-120) (25-13) Range (min - max) (11-20) (11-27) (11-27) (26-120) (25-13) Range (min - max) (11-20) (11-20) (11-20) (11-20) (11-20) Range (min - max) (11-20) (11-20) (11-20) (11-20) (11-20) Range (min - max) (11-20)						
range (min - max) (9-24) (9-21) (7-2) (1-21) <	15.5(3.4) 15.6(3.8) 13.6(3.8)	13.6(3.6)	16.9(4.2)	NA	15.3(4.0)	0.509
Time to peak (sec) 203(4.4) 18/9(3.8) 18/0(3.7) 208(4.3) range (min - max) (10–22) (13–30) (11–27) (13–27) (4–30) Washout time (sec) 41/4(19.4) 477(24.2) 87/3(3.47) 53:1(25.5) 62/4(3.6) mange (min - max) (15–120) (18–120) (18–120) (13–27) (14–30) mange (min - max) (15–120) (18–120) (18–120) (27–170) (25–120) (25–120) Intrablesional vessels (15–120) (18–120) (18–120) (27–170) (25–120) (25–120) Intrablesional vessels (11.8%) 0 (18–120) (27–170) (25–120) (25–13) Intrablesional vessels 1(1.9%) 53(4.1%) 4(19.0%) (26–130) (25–13) Intrablesional vessels 1(1.9%) 53(4.1%) 4(19.0%) (44.3%) (41.5.4%) Dotted 1(1.9%) 53(4.1%) 0 0 (44.3.%) (41.5.4%) Hornogeneous 16 (11.8%) 0 0 0 (43	(9–24) (9–27) (7–20)	(7–22)	(10–27)		(7–27)	
range (min - max) (10 - 32) (13 - 30) (11 - 27) (13 - 27) (14 - 30) Washout time (sec) 414(19.4) 477(24.2) 87.3(3.47) 53.1(25.5) 624(36) mange (min - max) (15 - 120) (18 - 120) (18 - 120) (27 - 170) (25 - 170) (25 - 170) Inange (min - max) (15 - 120) (18 - 120) (18 - 120) (27 - 170) (25 - 170) (25 - 170) Branched (11 - 804) (11 - 804) (11 - 804) (11 - 804) (15 - 160) (25 - 170) <	20.3(4.4) 18.9(3.8) 18.0(4.3)	18.0(3.7)	20.8(4.0)	NA	19.0(4.0)	0.028
Washout time (sec) 14.1(9.4) 4.7/2.4.2) 87.3(3.7) 53.1(2.5.5) 6.2.4(3) mange (min - max) (15-120) (15-120) (15-120) (25-170) (26-120) (25-170) Intralesional vessels (15-120) (15-120) (15-120) (15-120) (25-170)	(10–32) (13–30) (11–27)	(13–27)	(14–30)		(11–30)	
ange (min - max) (15-120) (18-120) (27-170) (26-120) (25-17) Intralesional vessels intrales	41.4(19.4) 47.7(24.2) 87.3(34.7	7) 53.1(25.5)	62.4(36.1)	NA	58.2(32.2)	< 0.001
Intralesional vessels 0 0 0 Branched 6 (11.8%) 0 0 0 0 Branched 6 (11.8%) 10 (15.9%) 17 (81.0%) 5 (35.7%) 15 (48.4) Dotted 11 (1.9%) 53 (84.1%) 10 (15.9%) 5 (35.7%) 16 (16.1%) Enhancement pattern 11 (1.9%) 53 (84.1%) 0 0 16 (31.4%) Inhonogeneous 16 (31.4%) 63 (100%) 0 0 17 (48.1%) 16 (43.9%) 17 (43.2%) Inhonogeneous 35 (86.6%) 0 0 0 17 (43.2%) 14 (43.2%) 17 (43.2%) Inhonogeneous 35 (86.6%) 0 0 0 17 (43.2%) 14 (43.2%) <td>(15–120) (18–120) (27–170)</td> <td>(26–120)</td> <td>(25–176)</td> <td></td> <td>(18–176)</td> <td></td>	(15–120) (18–120) (27–170)	(26–120)	(25–176)		(18–176)	
Branched 6 (11.8%) 0 0 0 0 Linear 44 (8.3%) 10(15.9%) 17(81.0%) 5(8.3%) 15(48.4 %) Dotted 1(1.9%) 53(4.1%) 17(81.0%) 5(8.3%) 16(51.6 %) Enhancement pattern 1(1.9%) 53(8.4%) 0 9(8.4.3%) 16(51.6 %) Homogeneous 1(1.9%) 63(100%) 23(100%) 2(100%) 9(8.4.3%) 16(51.6 %) Homogeneous 16 (31.4%) 0 0 0 17(54.8 %) 17(54.9 %) Inhomogeneous 35(8.6%) 0 0 0 9(8.4.3%) 17(54.8 %) 17(54.8 %) Inhomogeneous 35(8.6%) 0 0 0 14(4.8 %) 17(4.8 %) 17(4.8 %) Enhancement extent 3(5.9%) 13(20.6%) 13(20.6%) 13(2.9%) 13(2.9%) 14(4.8 %) 17(74.8 %) 14(4.8 %) 17(74.8 %) 14(7.8 %) 14(7.8 %) 14(7.9 %) 14(7.9 %) 14(7.9 %) 14(7.9 %) 14(7.9 %) 14(7.8 %) 14(7.8 %) <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td></td<>						
Linear 44 (86.3%) 10(15.9%) 17(81.0%) 9(64.3%) 15(43.4) Dotted 1(1.9%) 5(34.1%) 1(19.0%) 5(35.7%) 16(51.6) Enhancement pattern 1(1.9%) 5(34.1%) 21(100%) 9(64.3%) 16(51.6) Homogeneous 35(88.6%) 0 21(100%) 9(64.3%) 17(54.8) Inhomogeneous 35(88.6%) 0 0 5(35.7%) 16(31.4%) Homogeneous 35(88.6%) 0 0 1(100%) 9(64.3%) 14(45.2) Finhancement extent 35(88.6%) 0 0 0 1(44.8%) 1(44.8%) Arterial phase 3(5.9%) 13(20.6%) 1(4.8%) 1(7.1%) 28(90.3) Hyper 3(5.9%) 0 0 0 0 0 Hyper 3(5.9%) 13(20.6%) 1(4.8%) 1(7.1%) 3(97.6%) 3(97.6%) Hyper 3(5.9%) 13(20.6%) 1(4.8%) 1(7.1%) 28(97.6%) 28(97.6%) 28(97.6%) 28(97.6%) <	6 (11.8%) 0 0	0	0	NA	0	< 0.001
Dotted 1(1.9%) 5(3.4.1%) 4(19.0%) 5(3.5.7%) 16(51.6) Enhancement pattern 1 1 1 1 1 Homogeneous 16 (31.4%) 6 3(100%) 0 9(4.3%) 10(51.6) 10(51.6) Homogeneous 16 (31.4%) 6 3(100%) 0 0 9(4.3%) 17(54%) 17(54%) Inhomogeneous 35(68.6%) 0 0 0 9(64.3%) 10(45.8%) 10(45.8%) Inhomogeneous 35(68.6%) 0 0 0 9(64.3%) 10(45.8%)<	44 (86.3%) 10(15.9%) 17(81.0%	6) 9(64.3%)	15(48.4%)	NA	51 (39.5%)	
Enhancement pattern 17/548 Homogeneous 16 (31.4%) 63 (100%) 21 (100%) 9 (64.3%) 17/548 Homogeneous 35 (68.6%) 0 0 5 (35.7%) 1445.2 Inhomogeneous 35 (68.6%) 0 0 5 (35.7%) 1445.2 Enhancement extent 35 (68.6%) 0 0 5 (35.7%) 1445.2 Arterial phase 1 2 (00%) 2 (100%) 1 (445.2%) 1 (445.2%) 2 (30.9%) Hyper 3 (5.9%) 13 (20.6%) 1 (4.8%) 1 (7.1%) 2 (30.9%) Hyper 3 (5.9%) 0 0 0 0 0 Hyper 3 (5.9%) 0 0 0 0 0 Hyper 3 (5.9%) 1 (3 (20.6%) 1 (4.8%) 1 (7.1%) 2 (5.9%) Hyper 3 (5.9%) 0 0 0 0 0 Hyper 1 (1 (4.8%) 1 (4.8%) 1 (7.1%) 2 (5.9%) 2 (5.9%) Hyper 0 <	1(1.9%) 53(84.1%) 4(19.0%)	5(35.7%)	16(51.6%)	NA	78 (60.5%)	
Homogeneous 16 (31.4%) 63 (100%) 21 (100%) 9(64.3%) 17(3.48) Inhomogeneous 35 (68.6%) 0 5 (35.7%) 1445.2 Enhancement extent 35 (68.6%) 0 5 (35.7%) 1445.2 Frainal phase 1 1 1 1 1 Arterial phase 45 (88.2%) 5 0(79.4%) 2 (95.2%) 13 (92.9%) 2 (90.3 Hyper- 3 (5.9%) 13 (20.6%) 1 (4.8%) 1 (7.1%) 2 (90.3 Hyper- 3 (5.9%) 0 0 0 0 0 Hyper- 3 (5.9%) 0 0 0 0 0 Hyper- 0 0 0 0 0 0 0 Hyper- 0 0 0 0 0 0 0 0 Hyper- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0						
Inhomogeneous 35(86.6%) 0 6 5(35.7%) 14(45.2 Enhancement extent <td>16 (31.4%) 63(100%) 21(100%)</td> <td>9(64.3%)</td> <td>17(54.8%)</td> <td>NA</td> <td>110 (85.3%)</td> <td>< 0.001</td>	16 (31.4%) 63(100%) 21(100%)	9(64.3%)	17(54.8%)	NA	110 (85.3%)	< 0.001
Enhancement extent Arterial phase Arterial phase Arterial phase Hyper 45(88.2%) 50(79.4%) 20(95.2%) 13(92.9%) 28(903 Hyper 3(5.9%) 13(20.6%) 13(92.9%) 28(903 28(97%) 28(903 Hyper 3(5.9%) 3(5.9%) 0 0 0 0 0 Hyper 3(5.9%) 0	35(68.6%) 0 0	5(35.7%)	14(45.2%)	NA	19 (14.7%)	
Arterial phase 3(92.9%) 3(92.9%) 3(92.9%) 2(90.3 Hyper- 45(88.2%) 50(79.4%) 20(95.2%) 13(92.9%) 28(90.3 Hyper- 3(5.9%) 13(20.6%) 1(4.8%) 1(7.1%) 3(9.7%) Hyper- 3(5.9%) 0 0 0 0 0 Hyper- 3(5.9%) 0 0 0 0 0 0 Hyper- 3(5.9%) 0						
Hyper 45(83.2%) 50(79.4%) 20(95.2%) 13(22.9%) 28(90.3) Iso- 3(5.9%) 13(20.6%) 13(20.6%) 1(7.1%) 2(7%) 2(7%) Hypo- 3(5.9%) 3(5.9%) 0 0 0 2(7%) 2(97%) Hypo- 3(5.9%) 0 0 0 0 0 0 Hypo- 0 0 0 0 0 0 0 0 0 Hypo- 0 0 2(3.2%) 1(4.8%) 1(7.1%) 2(6.5%) 2(6.5%) Hypo- 0 0 0 0 0 0 2(6.5%) <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td></td<>						
Iso- 3(5,9%) 13(20,6%) 1(4,8%) 1(7,1%) 3(9,7%) Hypo- 3(5,9%) 0 0 0 0 0 Hypo- 3(5,9%) 0 0 0 0 0 0 Venous phase 3(5,9%) 0 0 0 0 0 0 0 Hypo- 0	45(88.2%) 50(79.4%) 20(95.2%	6) 13(92.9%)	28(90.3%)	NA	111(86.0%)	0.008
Hypo- 3(5.9%) 0 0 0 0 Hypor 0<	3(5.9%) 13(20.6%) 1(4.8%)	1(7.1%)	3(9.7%)	NA	18(14.0%)	
Venous phase 0 0 0 0 0 Hyper- 0 0 2(3.2%) 1(4.8%) 1(7.1%) 2(6.5%) Hypo- 51(100%) 61(96.8%) 20(95.2%) 13(32.9%) 29(93.5 Hypo- 51(100%) 61(96.8%) 20(95.2%) 13(92.9%) 29(93.5 Hypo- 51(100%) 61(96.8%) 20(95.2%) 13(92.9%) 29(93.5 Mall intactness 11(21.6%) 63(100%) 21(100%) 12(85.7%) 24(77.4 Intact 11(21.6%) 63(100%) 0 0 2(43.3%) 7(22.6%) Liver infiltration 10 0 0 0 2(4.3%) 7(22.6%)	3(5.9%) 0 0	0	0	NA	0	
Hyper- 0 0 0 0 0 0 0 1(7.1%) 2(5.5%) 1 1(7.1%) 2(5.5%) 1(7.1%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(5.5%) 2(7.5%) 2(10.5%) 2(10.5%) 2(17.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%) 2(12.5%)						
Iso- 0 2(3.2%) 1(4.8%) 1(7.1%) 2(6.5%) Hypo- 51(100%) 61(96.8%) 20(95.2%) 13(92.9%) 29(93.5 Wall intactness 51(100%) 61(96.8%) 20(95.2%) 13(92.9%) 29(93.5 Intact 11(21.6%) 63(100%) 21(100%) 12(85.7%) 24(74.4 Destructed 40(78.4%) 0 0 2(4.3%) 24(72.6% Liver infiltration 10 0 0 2(4.3%) 7(22.6%	0 0 0	0	0	NA	0	0.117
Hypo- 51(100%) 61(96.8%) 20(95.2%) 13(92.9%) 29(93.5 Wall interctness 13(92.9%) 13(92.9%) 29(93.5 29(93.5 Intact 11(21.6%) 63(100%) 21(100%) 12(85.7%) 24(77.4 Destructed 40(78.4%) 0 0 2(4.3%) 7(22.6%) Liver infiltration 1 10 1 1 1 1 1 1 2 1 1 2 1 2 1 2 1 1 1 2 1 2 1 2	0 2(3.2%) 1(4.8%)	1(7.1%)	2(6.5%)	NA	6 (4.7%)	
Wall intactness 21(100%) 12(85.7%) 24(77.4) Intact 11(21.6%) 63(100%) 21(100%) 12(85.7%) 24(77.4) Destructed 40(78.4%) 0 21(100%) 12(85.7%) 24(77.4) Liver infiltration 10(78.4%) 0 0 2(4.3%) 7(22.6%)	51(100%) 61(96.8%) 20(95.2%	6) 13(92.9%)	29(93.5%)	NA	123(95.3%)	
Intact 11(21.6%) 63(100%) 21(100%) 12(85.7%) 24(77.4 Destructed 40(78.4%) 0 0 2(4.3%) 7(22.6%) Liver infiltration Liver infiltration 1 1 2000000000000000000000000000000000000						
Destructed 40(78.4%) 0 0 2(4.3%) 7(22.6%) Liver infiltration 1	11(21.6%) 63(100%) 21(100%)	0) 12(85.7%)	24(77.4%)	1 2(1 00%)	132(93.6%)	< 0.001
Liver infiltration	40(78.4%) 0 0	2(4.3%)	7(22.6%)	0	9(6.4%)	
Present 26(51.0%) 0 0 0 1(3.2%)	26(51.0%) 0 0	0	1 (3.2%)	0	1(0.7%)	< 0.001
Absent 25(49.0%) 63(100%) 21(100%) 14(100%) 30(96.8)	25(49.0%) 63(100%) 21(100%)	14(100%)	30(96.8%)	1 2(1 00%)	140(99.3%)	

.

applicable. doi:10.1371/journal.pone.0048371.t002



Figure 4. Cholesterol polyp in gallbladder. Upper left, color flow imaging shows intralesional vascularity in the polyp (arrow); Upper right, the lesion (arrow) shows hyper-enhancement during the arterial phase; Lower left, the lesion (arrow) shows iso-enhancement during the venous phase. doi:10.1371/journal.pone.0048371.g004

The baseline US and CEUS were analyzed by the same investigators with the baseline US images evaluated in advance of CEUS images. The US features of the gallbladder lesions were documented: echogenicity (hyperechoic, isoechoic, hypoechoic, mixed); location (bottom, body, neck, whole GB); morphological type (polypoid type, thickened-wall type, mass-forming type) (Fig. 1); feature of the lesion bottom (narrow, broad, not applicable). Color Doppler imaging was then used to assess the lesion vascularity. The vascularity was classified as abundant, scarce, or none.

On CEUS, the contrast arrival time to the lesions, contrast arrival time to the adjacent liver parenchyma, time to peak enhancement in the lesions, and time to hypo-enhancement (washout time) were recorded. The intralesional vascularity during the arterial phase was categorized into branched, linear, dotted, and none (Fig. 1). The enhancement pattern was classified as homogeneous and inhomogeneous. The enhancement extent during the arterial phase and venous phase was evaluated to be hyper-, iso-, hypo-, or non-enhancement, with the reference to the adjacent normal liver tissue (Fig. 2). The GB wall under the GB lesions was divided into intact and destructed (Fig. 3). Destruction of the intactness was defined as the continuity of the gallbladder wall was incomplete. The infiltration to the adjacent liver tissue was documented to be present or absent.

Statistical Analysis

The continuous data were expressed as mean (std). The comparison between the categorical data was tested using the x^2 test or Fisher exact probability test. The comparison between the continuous data was tested using the independent t test if normal distribution was achieved; otherwise, nonparametric Mann-Whitney U test was used. A multiple logistic regression analysis was performed to select independent variables of patient characteristics, baseline US findings, and CEUS features associated with the dependent variable (i.e., the benign nature of the lesion). The independent variables were listed in Table 1 and Table 2. In the multiple logistic regression analysis, all the independent variables were firstly included as covariates. Dummy variables were allocated to the unordered categorical variables, such as the echogenicity, location, morphological type, and intralesional vessels on CEUS, and indicator coding was performed for the unordered categorical variables [17]. For the dichotomous variables and the ordered categorical variables, dummy variables were not allocated. The forward stepwise selection method was used. The independent variables with Pvalues of less than 0.05 in the multiple logistic regression analysis were selected for receiver operating characteristic (ROC) curve analysis. The diagnostic performance for each significant independent variable was expressed as the area under



Figure 5. Adenomyomatosis in gallbladder. Upper left, conventional ultrasound shows a slight hypoechoic mass (arrow) in the gallbladder; Upper right, the lesion (arrow) shows inhomogeneous hyper-enhancement during the arterial phase; Lower left, the lesion (arrow) shows hypoenhancement during the venous phase. doi:10.1371/journal.pone.0048371.g005

the ROC curve (Az). The higher the Az value, the higher the diagnostic performance [18]. The Az value ranges from 0.5 to 1. The diagnostic value is regarded as low for Az of 0.5–0.7, moderate for Az of 0.7–0.9, and high for Az greater than 0.9. The cut-off value for each significant independent variable, as well as the associated sensitivity and specificity, were obtained from the ROC analysis. A multiple logistic regression model was established using the significant independent variables and the Az value of the combination of the significant independent variables was calculated. Two-tailed P values of less than 0.05 were accepted as showing statistical significance. The statistical analyses were performed using the SPSS 13.0 software package (SPSS, Chicago, IL).

Results

Final Diagnosis

The majority of the GB diseases were histologically confirmed (n = 184, 95.8%) with specimens after surgery, and the remaining 8 cases (4.2%) were confirmed by surgery. The final diagnoses of the 192 patients included GB adenocarcinoma (n = 51), cholesterol polyp (n = 63), adenomas (n = 21), adeno-

myomatosis (n = 14), chronic cholecystitis (n = 31), and biliary sludge (n = 12) (Table 1).

Comparisons between Malignant and Benign GB Diseases in Basic and Baseline US Characteristics

There were significant differences between malignant and benign GB diseases in patient age, lesion number, lesion size, and lesion location (all P < 0.05). Malignant GB diseases were more often encountered in elder patients, patients with solitary lesion, lesions greater than 3.0 cm in diameter, and lesions affecting the whole GB (Table 1).

With regard to the morphological type, malignant GB diseases were more commonly found in lesions with thickened wall and mass-forming type (P < 0.001) (Table 1). There were significant differences between lesion echogenicity on gray-scale US and intralesional flow signals on color Doppler imaging, with malignant GB diseases more often to be hypocchoic and to show abundant intralesional flow signals (all P < 0.05) (Table 1).



Figure 6. Adenoma in gallbladder. Upper left, conventional ultrasound shows an isoechoic mass (calipers) in the gallbladder; Upper right, pulsatile arterial blood flow is detected in the lesion; Middle left, the lesion (arrow) shows linear blood vessels during the arterial phase; Middle right, the lesion (arrow) shows hyper-enhancement during the arterial phase; Lower left, the lesion (arrow) shows iso-enhancement during the venous phase.

doi:10.1371/journal.pone.0048371.g006

Comparisons between Malignant and Benign GB Diseases in CEUS Characteristics

The washout time for the malignant GB diseases was quicker than that for the benign GB diseases (P=0.001) (Table 2). During the arterial phase, the intralesional blood vessels were more often to be branched or linear in the malignant GB diseases whereas dotted in the benign diseases (P<0.001) (Table 2). Homogeneous enhancement was more easily found in benign GB diseases whereas inhomogeneous enhancement in malignant GB diseases (P<0.001) (Table 2) (Figs. 4, 5, 6, 7). There was significant difference between malignant and benign GB diseases in enhancement extent during the arterial phase (P=0.008) (Table 2). GB wall destruction beneath the lesions and liver infiltration were more often encountered in malignant GB diseases (both P<0.001) (Table 2) (Fig. 7).

Multiple Logistic Regression Analysis to Select the Independent Variables Associated with the Nature of the GB Diseases

All the independent variables in Tables 1 and 2 were submitted to multiple logistic regression analysis. The results showed that the following independent variables were associated with the benign nature of the GB diseases, including the patient age, intralesional vessels on CEUS, contrast washout time, and wall intactness depicted on CEUS (all P < 0.05) (Table 3).

ROC Analyses for the Independent Variables

The results of the ROC analyses for the significant independent variables were listed in Table 4. The results showed that the patient age, intralesional vessels on CEUS, and the intactness of the GB wall depicted on CEUS yielded an Az value greater than 0.8 in each whereas the Az value for the washout time was only 0.669 (Table 4).



Figure 7. Adenocarcinoma in gallbladder. Upper left, conventional ultrasound shows an isoechoic mass (arrow) and a stone (arrowhead) in the gallbladder; Upper right, color flow imaging shows intralesional vascularity (arrow); Lower left, the lesion (arrow) shows hyper-enhancement during the arterial phase and the infiltration (arrowhead) to the adjacent liver is seen; Lower right, the lesion (arrow) shows hypo-enhancement during the venous phase and the infiltration (arrowhead) to the adjacent liver is seen. doi:10.1371/journal.pone.0048371.q007

Table 3. The independent variables associated with the GB benign diseases by multiple logistic regression analysis.

	В	Odds ratio	95% CI	<i>P</i> Value
Age (yrs)	-0.156	0.856	0.795–0.922	< 0.001
Intralesional vessels on CEUS*				0.002
Branched vs. Dotted	-23.158	0.000	0.000-NA	0.999
Linear vs. Dotted	-4.314	0.013	0.001-0.153	0.001
Wash-out time (sec)	0.064	1.066	1.025-1.110	0.002
Wall intactness on $CEUS^\#$	-2.945	0.053	0.012-0.230	< 0.001
Constant	14.066	1285078.5	NA	< 0.001

*The reference group is dotted intralesional vessels. # The reference group is intact wall on CEUS.

A multiple logistic regression model was established using the significant independent variables as following:

P =

1	
$1 + \exp[-(14.066 - 0.156 \cdot X_1 - 23.158 \cdot X_2 - 4.314 \cdot X_3 + 0.064 \cdot X_4 - 2.945 \cdot X_5 + 0.064 \cdot X_$	5)]

P indicated probability; X_1 indicated patient age; X_2 indicated intralesional vessels on CEUS (branch vs. dotted); X_3 indicated intralesional vessels on CEUS (branch vs. dotted); X_4 indicated washout time; X_5 indicated wall intactness.

ROC analysis showed that the Az value of the combination of the four significant independent variables was 0.915 (95%) confidence interval: 0.857-0.974 (P < 0.001).

Discussion

Conventional US is undoubtedly the first-line imaging investigation for the diagnosis of GB diseases, whereas it may face difficulty in determining the nature of the GB lesions in some complicated cases. The role of US is limited in differentiating chronic cholecystitis with thickened wall from GB carcinoma with thickened wall, differentiating motionless sludge from GB cancer, detecting GB cancer when more than two types of GB diseases are present or the lesions fill the GB. Besides that, the destruction of the GB wall beneath the lesion, and the infiltration to the adjacent liver tissue, is hard to be visible by conventional US, whereas these two features are highly suggestive of malignancy [3,4,5] (Table 5).

The successful use of CEUS in other organs such as liver, kidney, and pancreas has prompted the use of CEUS in GB [13,15,19]. Unfortunately, its usefulness in GB is controversial. Kato et al [20] found that there was no difference between cholesterol polyp and polypoid GB cancer in either enhancement pattern or the duration of the enhancement on CEUS. Inoue et al [5] concluded that vascular pattern may simply reflect the size of the lesion and the usefulness of CEUS in diagnosing GB lesions may be limited. In the 2011 non-liver CEUS guideline, the panel experts agreed that the differentiation between benign and malignant GB lesions is mainly determined by clinical features and size and enlargement of polyps to >10 mm is an indication for cholecystectomy. According to the guideline, more sophisticated classification of the vascular and enhancement pattern of GB lesions on CEUS has not been introduced so far in the clinical routine and CEUS currently has no role in differentiating benign from malignant GB polyps [10].

On the other hand, Hirooka et al [3] found that GB cancer showed enhancement, whereas cholesterol polyp showed nonenhancement using endoscopic US and air-filled microspheres created by sonication of a 5% solution of human serum albumin. The accuracy of depth of tumor invasion for endoscopic US was 78.6% versus 92.9% for contrast-enhanced endoscopic US. The authors concluded that contrast-enhanced endoscopic US is useful in the diagnosis of GB lesions. Numata et al [11] proposed tumor enhancement and tortuous-type tumor vessels on CEUS as diagnostic criteria for GB carcinomas, and the sensitivity, specificity, and accuracy of CEUS were 75%, 100%, and 91%, respectively. The authors concluded that evaluation of tumor vessels on CEUS may be useful for differentiating GB carcinoma from other polypoid gallbladder lesions [11]. Hattori et al [21] reported that when diffuse type and branched type tumor vessels were considered as indicative of cancer, the sensitivity, specificity, and accuracy were 100%, 76.9%, and 84.5%, respectively. Tusji et al [14] indicated that branched tumor vessels were possibly the characteristic of GB malignancy. Xie et al [4] found that destruction of GB wall intactness on CEUS yielded the highest capability in differential diagnosis, with sensitivity and specificity of 84.8% and 100% respectively.

To further evaluate whether CEUS is useful in the diagnosis of GB diseases, this multicenter study was carried out to assess the performance of CEUS in the diagnosis of GB diseases and find out the diagnostic criteria for GB malignancy. Multiple logistic regression analysis showed that the following independent variables were associated with the benign nature of the GB diseases, including the patient age, intralesional vessels on CEUS, contrast washout time, and wall intactness depicted on CEUS. The ROC analyses showed that the patient age, intralesional vessels on CEUS, and GB wall intactness on CEUS achieved the highest diagnostic performance in differentiating malignant from benign GB diseases, with Az value ranged from 0.805 to 0.857 respectively. The sensitivity and specificity were 59.8%-92.2% and 49%-98.0% respectively. The study was consistent with the previous studies that branched or linear intralesional vessels on CEUS and the destruction of GB wall were possibly the

Table 4. ROC analyses of the independent variables in differentiating malignant from benign GB diseases.

	Az*	Cut-off value	Sensitivity	Specificity
Age	0.805 (0.746-0.863)	53.5 y	92.2%	59.6%
Intralesional vessels on CEUS	0.813 (0.751–0.875)	dotted	59.8%	98.0%
Wash-out time	0.669 (0.585–0.753)	36.5 s	74.8%	49%
Wall intactness on CEUS	0.857 (0.786–0.928)	intact wall	78.4%	92.9%

*Numbers in the parenthesis indicate 95% confidence interval.

doi:10.1371/journal.pone.0048371.t004

Table 5. The advantage of CEUS measures over conventional US in the diagnosis of GB diseases.

	CEUS	Conventional US
Depiction of the lesion features		
Width of the fundus	++	+
Destruction of the wall	+++	+
Infiltration to the adjacent liver tissue	+++	+
Metastasis to the liver	+++	+
Macro-vascularity	+++	+
Micro-vascularity	+++	-
Dynamic perfusion	+++	-
Diagnosis		
Differentiating chronic cholecystitis with thickened wall from GB carcinoma with thickened wall	+++	+
Differentiating motionless sludge from GB cancer	++++	+
Differentiating polyps or adenoma from polypoid GB cancer	+++	++
Detecting GB cancer when more than two types of GB diseases are present or the lesions fill the GB	+++	+

"+" means positive and "-" means negative.

doi:10.1371/journal.pone.0048371.t005

characteristics of GB malignancy and might be the diagnostic criteria of GB malignancy on CEUS [4,11,14,21] (Table 5).

In this study, the majority of both GB carcinomas (88.2%, 45/ 51) and benign GB diseases (78.7%, 111/141) appeared as hyperenhancing in the arterial phase, therefore, hyper-enhancing in the arterial phase and washout in the venous phase is not a clue for GB malignancy. On the other hand, all the carcinomas (100%, 51/51) and 87.2% (123/141) of benign GB diseases appeared as hypo-enhancing in the venous phase, thus hypo-enhancing in the venous phase can not be used for distinction between malignant and benign GB diseases, which is not like what happened in the diagnosis of liver malignancy [9]. However, the contrast washout time for the malignant and benign GB showed significant difference (41.4 s versus 58.2 s) and the ROC analysis also showed that the Az value did achieve statistical significance.

Despite of the controversies over the usefulness of CEUS in GB as mentioned above, nearly all the investigators agreed that CEUS is clearly superior to the other techniques in discriminating biliary sludge from other GB lesions [4,5,14]. The absence of enhancement in biliary sludge allows differentiation from a tumor, which enhances, in almost all cases on CEUS [4,5,10,14]. In the cases of GB malignancy, the role of CEUS to detect infiltration of the surrounding liver parenchyma and to exclude liver metastases has been endorsed [10,14]. In the case of acute cholecystitis, the detection or exclusion of abscess formation in the surrounding liver parenchyma is important and can be performed with CEUS, although published evidence is sparse so far. Interruption of the gallbladder wall suggests perforation, which can be confirmed by the absence of enhancement of the perforated wall [10] (Table 5).

In addition to the CEUS feature, this study found that the patient age is also a major factor for differential diagnosis between benign and malignant GB diseases. Patient age less than 53.5 yrs

References

- Inui K, Yoshino J, Miyoshi H (2011) Diagnosis of gallbladder tumors. Intern Med 50: 1133–1136.
- Xu HX, Yin XY, Lu MD, Liu L, Yue DC, et al. (2003) Comparison of threeand two-dimensional sonography in diagnosis of gallbladder diseases: preliminary experience. J Ultrasound Med 22: 181–191.
- Hirooka Y, Naitoh Y, Goto H, Ito A, Hayakawa S, et al. (1998) Contrastenhanced endoscopic ultrasonography in gallbladder diseases. Gastrointest Endosc 48: 406–410.

was more often observed in benign GB diseases. Several studies also have proven that gallbladder cancer increases with age and patient age >60 yrs is a major risk factor for malignant GB diseases [22,23].

The primary goal of this study was to evaluate the diagnostic performance of CEUS in the differential diagnosis between malignant and benign GB diseases, thus the comparisons between baseline US and CEUS were not performed. Future studies in this regard are necessary to determine the real impact of CEUS in clinical practice. In addition, a prospective study is needed to confirm the accuracy of the proposed diagnostic criteria for GB diseases.

In conclusion, the multicenter experience of CEUS in GB diseases confirmed that CEUS is valuable in the differential diagnosis between malignant and benign GB diseases. The branched or linear intralesional vessels on CEUS and destruction of GB wall are the CEUS features highly suggestive of GB malignancy and the patient age >53.5 yrs is also a clue for GB malignancy.

Acknowledgments

The authors would like to express their gratitude to Zi-Sheng Ai, PhD from the Department of Preventive Medicine, College of Medicine, Tongji University, Shanghai, China, for his assistance in statistical analysis.

Author Contributions

Conceived and designed the experiments: H-XX M-DL. Performed the experiments: L-NL H-XX X-YX W-PW BH KY HD S-ST L-XQ B-ML Y-LW. Analyzed the data: L-NL H-XX M-DL. Contributed reagents/ materials/analysis tools: H-XX M-DL. Wrote the paper: L-NL H-XX M-DL.

- Xie XH, Xu HX, Xie XY, Lu MD, Kuang M, et al. (2010) Differential diagnosis between benign and malignant gallbladder diseases with real-time contrastenhanced ultrasound. Eur Radiol 20: 239–248.
- Inoue T, Kitano M, Kudo M, Sakamoto H, Kawasaki T, et al. (2007) Diagnosis of gallbladder diseases by contrast-enhanced phase-inversion harmonic ultrasonography. Ultrasound Med Biol 33: 353–361.
- Xu XH (2009) Contrast-enhanced ultrasound in the biliary system: potential uses and indications. World J Radiol 1: 37–44.

- Lin MX, Xu HX, Lu MD, Xie XY, Chen LD, et al. (2009) Diagnostic performance of contrast-enhanced ultrasound for complex cystic focal liver lesions: blinded reader study. Eur Radiol 19: 358–369.
- Chen LD, Xu HX, Xie XY, Xie XH, Xu ZF, et al. (2010) Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 20: 743–753.
- Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, et al. (2008) Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med 29: 28–44.
- Piscaglia F, Nolsøe C, Dietrich CF, Cosgrove DO, Gilja OH, et al. (2012) The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med 33: 33–59.
- Numata K, Oka H, Morimoto M, Sugimori K, Kunisaki R, et al. (2007) Differential diagnosis of gallbladder diseases with contrast-enhanced harmonic gray scale ultrasonography. J Ultrasound Med 26: 763–774.
- Adamietz B, Wenkel E, Uder M, Meyer T, Schneider I, et al. (2007) Contrast enhanced sonography of the gallbladder: a tool in the diagnosis of cholecystitis? Eur J Radiol 61: 262–266.
- Kumagai Y, Kotanagi H, Ishida H, Komatsuda T, Furukawa K, et al. (2006) Gallbladder adenoma: report of a case with emphasis on contrast-enhanced US findings. Abdom Imaging 31: 449–452.
- Tsuji S, Sofuni A, Moriyasu F, Itokawa F, Ishii K, et al. (2012) Contrastenhanced ultrasonography in the diagnosis of gallbladder disease. Hepatogastroenterology 59: 336–340.

- Ueda J, Yoshida H, Arima Y, Mamada Y, Taniai N, et al. (2011) A case of xanthogranulomatous cholecystitis preoperatively diagnosed with contrastenhanced ultrasonography. J Nihon Med Sch 78: 194–198.
- Zechner PM, Rienmüller S, Dorr K, Genger C, Wurzer H (2012) Contrastenhanced ultrasound detects gallbladder perforation in a patient with acute abdominal pain. Am J Emerg Med 30: 516.e5–6.
- Cleophas TJ, Atiqi R, Zwinderman AH (2012) Handling categories properly: a novel objective of clinical research. Am J Ther 19: 287–293.
- Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29–36.
- Meacock LM, Sellars ME, Sidhu PS (2010) Evaluation of gallbladder and biliary duct disease using microbubble contrast-enhanced ultrasound. Br J Radiol 83: 615–627.
- Kato T, Tsukamoto Y, Naitoh Y, et al. (1994) Ultrasonographic angiography in gallbladder diseases. Acta Radiol 35: 606–613.
- Hattori M, Inui K, Yoshino J, Miyoshi H, Okushima K, et al. (2007) Usefulness of contrast-enhanced ultrasonography in the differential diagnosis of polypoid gallbladder lesions.[Article in Japanese] Nihon Shokakibyo Gakkai Zasshi 104: 790–798.
- Stinton LM, Shaffer EA (2012) Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 6: 172–187.
- Kwon W, Jang JY, Lee SE, Hwang DW, Kim SW (2009) Clinicopathologic features of polypoid lesions of the gallbladder and risk factors of gallbladder cancer. J Korean Med Sci 24: 481–487.